Jaguar Health (JAGX) closed at $0.42 on November 13, 2026, up 4.7% from the previous close, on volume of 417,212 shares (30-day average 2,441,256).
Data as of November 13, 2026.
Jaguar Health to Hold Investor Webcast November 17 Regarding Q3 2026 Financials & Corporate Updates
ACCESS Newswire (Fri, 13-Nov 9:00 AM ET)
Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
ACCESS Newswire (Fri, 6-Nov 4:15 PM ET)
ACCESS Newswire (Mon, 2-Nov 9:00 AM ET)
ACCESS Newswire (Wed, 21-Oct 9:00 AM ET)
Jaguar Health Provides Update Regarding Special Stock Dividend
ACCESS Newswire (Wed, 14-Oct 4:15 PM ET)
ACCESS Newswire (Wed, 14-Oct 9:00 AM ET)
Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend
ACCESS Newswire (Tue, 13-Oct 9:00 AM ET)
JAGX rallies as Napo highlights pediatric intestinal failure program and targets mid-2027 MVID NDA
Market Chameleon (Tue, 6-Oct 5:52 AM ET)
ACCESS Newswire (Tue, 6-Oct 9:05 AM ET)
JAGX Jumps After Declaring a Special Stock Dividend That Converts Into Five Common Shares
Market Chameleon (Mon, 5-Oct 6:25 AM ET)
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Jaguar Health trades on the NASDAQ stock market under the symbol JAGX.
As of November 13, 2026, JAGX stock price climbed to $0.42 with 417,212 million shares trading.
JAGX has a beta of 6.52, meaning it tends to be more sensitive to market movements. JAGX has a correlation of 0.09 to the broad based SPY ETF.
JAGX has a market cap of $5.59 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, JAGX traded as high as $405,081.90 and as low as $.36.
JAGX has underperformed the market in the last year with a price return of -100.0% while the SPY ETF gained +13.4%. JAGX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -96.4% and -74.1%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
JAGX support price is $.34 and resistance is $.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JAGX shares will trade within this expected range on the day.
